Stem Cells: Encouraging cartilage production
A long non-coding RNA called GRASLND is essential to help stem cells create stable cartilage.
- Orthopaedics and Rehabilitation, Oregon Health Science University, United States
- Skeletal Biology Research Center, Shriners Hospital for Children, United States
Recently watching a rerun of the 2016 Olympics gymnastics finals, I could not help marveling at the way the joints of the athletes could withstand so many gravity-defying leaps, twists, and landings. These feats are possible because the ends of our bones are covered by articular cartilage, a smooth tissue that allows fluid, pain-free movement. This tissue is made by specialized cells secreting proteins that trap water and form an extracellular matrix which cushions joints.
When articular cartilage wears away, for example in degenerative diseases such as osteoarthritis, movements become painful and quality of life drops severely. Yet, these conditions are increasingly common – in the United States alone, it is predicted that more than 78 million people could be affected by 2040 (Hootman et al., 2016).
Cartilage is not connected to the nervous system or to blood and lymphatic vessels, which means the tissue heals poorly when damaged. Most therapies for osteoarthritis therefore work by preserving the remaining cartilage or preventing further loss. Once the cartilage is lost, few interventions exist: surgeons can carefully damage the bone to promote the creation of new tissue, they can graft bone and cartilage obtained from a donor, or they can completely replace the joints with artificial ones (Steadman et al., 2001; Toh et al., 2014; Bugbee et al., 2016; Migliorini et al., 2020). However, these interventions may not be durable, and they are limited by factors such as the availability of donor tissue and the age or health condition of the patient.
Another, lab-based approach is to harvest mesenchymal stem cells or chondroprogenitor cells from patients, and then 'coax' these to create cartilage that can be implanted in the individual (Migliorini et al., 2020). However, one challenge associated with this method is the stability of the resulting cartilage: over time, it can change into bone, reducing the function of the repaired joint.
Long non-coding RNAs are molecules that regulate an array of genetic events in the cell, and it was reported recently that these sequences are essential to keep cartilage stable: for instance, several long non-coding RNAs are activated in mesenchymal stem cells that produce cartilage (Barter et al., 2017; Huynh et al., 2019). Now in eLife, Farshid Guilak and colleagues – including Nguyen Hyunh as first author – report having identified a long non-coding RNA called GRASLND which encourages mesenchymal stem cells to produce molecules that form cartilage (Huynh et al., 2020).
First, the team (which is based at Washington University in St. Louis, the St. Louis Shriners Hospital, Duke University and Vanderbilt University) designed RNA molecules that were used to deactivate GRASLND in mesenchymal stem cells. As a result, the production of cartilage decreased and these cells started to show a molecular profile associated with bone formation. These results demonstrate that, in these cells, GRASLND is required to maintain a cartilage-forming program (Figure 1).
Figure 1
GRASLND helps mesenchymal stem cells to create cartilage by suppressing IFN-signaling.
(A) Exposing mesenchymal stem cells (MSCs) to the growth factor TGFβ3 activates the expression of the Sox9 gene, which triggers the production of a long non-coding RNA called GRASLND. (B) GRASLND binds to the kinase EIF2AK2 (blue), which blocks the inhibitory phosphorylation of the protein EIF2A (green). This, in turn, promotes the expression of 'prochondrogenic factors' that encourage the production of molecules, such as proteoglycans, which form cartilage; the cell is said to have a 'chondrogenic' phenotype. (C) When GRASLND is depleted from mesenchymal stem cells, the kinase EIF2AK2 probably phosphorylates EIF2A (represented here by the ‘-P*’). This activates the Type II IFN-γ response, which ultimately leads to a reduction in proteoglycan expression and a loss of the chondrogenic phenotype. GRASLND: glycosaminoglycan regulatory associated long non-coding RNA; EIF2A: eukaryotic translation initiation factor two alpha; EIF2AK2: EIF2A kinase; TGFβ3: transforming growth factor beta 3. Figure created using BioRender (BioRender.com).
Further experiments showed that GRASLND interacts with EIF2AK2, a kinase that normally inhibits a protein known as EIF2A, which triggers a molecular cascade called the type II IFN-γ signaling pathway (Samuel, 1979; Platanias, 2005). This pathway is essential for the immune system, but some of its elements, such as a cytokine called IFN-γ, also help to stimulate bone formation (Duque et al., 2011).
When GRASLND binds EIF2AK2, it probably stops this kinase from acting on EIF2A; this suppresses IFN activity while allowing the genes that promote the production of cartilage to be expressed (Figure 1B). On the other hand, Hyunh et al. find that removing GRASLND is associated with an increase in the expression of genes under the control of IFN-γ (Figure 1C). As IFN-γ promotes bone formation, these findings explain why depleting mesenchymal stem cells of GRASLND leads to more bone production.
Finally, Hyunh et al. used data mining to show that, in diseased cartilage, genes regulated by IFN are expressed more abundantly. This suggests that IFN-signaling may be directly responsible for the production of the abnormal, bony nodules that are often present in osteoarthritic cartilage.
Overall, these results indicate that — at least in vitro — GRASLND is an important modulator of type II IFN-γ signaling that is necessary for cartilage differentiation. They also highlight that this pathway may be involved in diseases of the cartilage. If so, the interaction between GRASLND and EIF2AK2 could be an important pharmacological target. Exploring this possibility will first require comparing the expression of GRASLND in healthy and diseased cartilage.
GRASLND has only been found in primates, but related long non-coding RNAs could be identified in other species by spotting the motifs that GRASLND needs to interact with EIF2AK2. In turn, this knowledge could pave the way for better animal models to study how this class of long non-coding RNAs is involved in degenerative joint diseases.
References
-
Interferon-γ plays a role in bone formation in vivo and rescues osteoporosis in ovariectomized miceJournal of Bone and Mineral Research 26:1472–1483.https://doi.org/10.1002/jbmr.350
-
Mechanisms of type-I- and type-II-interferon-mediated signallingNature Reviews Immunology 5:375–386.https://doi.org/10.1038/nri1604
-
Microfracture: surgical technique and rehabilitation to treat chondral defectsClinical Orthopaedics and Related Research 391:S362–S369.https://doi.org/10.1097/00003086-200110001-00033
-
Advances in mesenchymal stem cell-based strategies for cartilage repair and regenerationStem Cell Reviews and Reports 10:686–696.https://doi.org/10.1007/s12015-014-9526-z
Article and author information
Author details
Publication history
- Version of Record published: May 6, 2020 (version 1)
Copyright
© 2020, Stadler
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 859
- views
-
- 50
- downloads
-
- 1
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Stem Cells: Encouraging cartilage production
eLife 9:e57239.
https://doi.org/10.7554/eLife.57239
Further reading
-
- Developmental Biology
- Stem Cells and Regenerative Medicine
Hematopoietic stem cells emerge in the embryo from an aortic-derived tissue called the hemogenic endothelium (HE). The HE appears to give birth to cells of different nature and fate but the molecular principles underlying this complexity are largely unknown. Here we show, in the zebrafish embryo, that two cell types emerge from the aortic floor with radically different morphodynamics. With the support of live imaging, we bring evidence suggesting that the mechanics underlying the two emergence types rely, or not, on apicobasal polarity establishment. While the first type is characterized by reinforcement of apicobasal polarity and maintenance of the apical/luminal membrane until release, the second type emerges via a dynamic process reminiscent of trans-endothelial migration. Interfering with Runx1 function suggests that the balance between the two emergence types depends on tuning apicobasal polarity at the level of the HE. In support of this and unexpectedly, we show that Pard3ba – one of the four Pard3 proteins expressed in the zebrafish – is sensitive to interference with Runx1 activity, in aortic endothelial cells. This supports the idea of a signaling cross talk controlling cell polarity and its associated features, between aortic and hemogenic cells. In addition, using new transgenic fish lines that express Junctional Adhesion Molecules and functional interference, we bring evidence for the essential role of ArhGEF11/PDZ-RhoGEF in controlling the HE-endothelial cell dynamic interface, including cell-cell intercalation, which is ultimately required for emergence completion. Overall, we highlight critical cellular and dynamic events of the endothelial-to-hematopoietic transition that support emergence complexity, with a potential impact on cell fate.
-
- Stem Cells and Regenerative Medicine
A causal relationship exists among the aging process, organ decay and disfunction, and the occurrence of various diseases including cancer. A genetically engineered mouse model, termed Klf1K74R/K74R or Klf1(K74R), carrying mutation on the well-conserved sumoylation site of the hematopoietic transcription factor KLF1/EKLF has been generated that possesses extended lifespan and healthy characteristics, including cancer resistance. We show that the healthy longevity characteristics of the Klf1(K74R) mice, as exemplified by their higher anti-cancer capability, are likely gender-, age-, and genetic background-independent. Significantly, the anti-cancer capability, in particular that against melanoma as well as hepatocellular carcinoma, and lifespan-extending property of Klf1(K74R) mice, could be transferred to wild-type mice via transplantation of their bone marrow mononuclear cells at a young age of the latter. Furthermore, NK(K74R) cells carry higher in vitro cancer cell-killing ability than wild-type NK cells. Targeted/global gene expression profiling analysis has identified changes in the expression of specific proteins, including the immune checkpoint factors PDCD and CD274, and cellular pathways in the leukocytes of the Klf1(K74R) that are in the directions of anti-cancer and/or anti-aging. This study demonstrates the feasibility of developing a transferable hematopoietic/blood system for long-term anti-cancer and, potentially, for anti-aging.
